<DOC>
	<DOCNO>NCT00370097</DOCNO>
	<brief_summary>The purpose study address Food Drug Administration ( FDA ) request provide safety data pre-asthmatic patient , age 6 month &lt; 12 month , follow administration fluticasone propionate HFA .</brief_summary>
	<brief_title>FLOVENT Hydrofluoroalkane ( HFA ) In 6-12 Month Old Subjects</brief_title>
	<detailed_description>A repeat-dose , open-label , 2-session study assess systemic exposure , pharmacodynamics , fluticasone propionate HFA inhalation aerosol 88mcg administer twice-daily 28 day deliver via MDI valved hold chamber infant facemask subject age 6 month &lt; 12 month experience 2 wheeze episode precede 6 month</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Subjects experience 2 wheeze episode previous 6 month . Subjects may take corticosteroid 4 week prior dose Parents/guardians able read comprehend diary information collect throughout study Parents must able demonstrate ability use facemask spacer use administer study drug Exclusion criterion : Subjects weigh less 7 kg Subjects take drug inhibit induce cytochrome P450 isoform Any parent history psychiatric disease , intellectual deficiency , substance abuse would compromise validity consent</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Asthma infant FLOVENT spacer</keyword>
</DOC>